Moors & Cabot to pay $1.9M for conflict of interest disclosure lapses
By 
Adrianne Appel2023-01-20T21:21:00
Massachusetts-based investment adviser Moors & Cabot reached an approximately $1.9 million settlement with the Securities and Exchange Commission (SEC) over allegations the firm didn’t fairly disclose conflicts of interest associated with incentive payments it received from two unaffiliated clearing brokers.
The firm was also censured after it failed to implement written compliance policies and procedures aimed at preventing violations of the Advisers Act, according to the SEC’s order filed Thursday.
The two clearing brokers executed securities transactions and handled related recordkeeping on behalf of Moors & Cabot between at least February 2017 and September 2021, the SEC stated. Services they provided included transferring customers’ uninvested cash into interest-bearing bank accounts, called cash sweep programs, and providing loans so customers could buy securities.
Related articles
-
News BriefWells Fargo fined $35M, Merrill Lynch $25M over improper cash sweeps
Wells Fargo and Merrill Lynch will pay $35 million and $25 million, respectively, to settle allegations by the Securities and Exchange Commission that their handling of investment accounts’ cash sweep programs violated federal law.
-
News BriefPIMCO to pay $9M in SEC disclosure, policy failure settlements
Pacific Investment Management Company agreed to pay a combined $9 million to resolve two separate actions brought by the Securities and Exchange Commission regarding alleged violations of the Advisers Act.
-
News Brief
SEC fines Corvex Management $1M for SPACs conflicts
Corvex Management agreed to pay $1 million to settle allegations it failed to disclose personnel ownership in certain sponsors of special purpose acquisition companies and didn’t have policies and procedures reasonably designed to thwart conflicts of interest.
More from Regulatory Enforcement
-
News BriefCFPB ends probe into Meta’s financial advertising practices
Meta says it is no longer under investigation by the U.S. Consumer Financial Protection Bureau (CFPB), the latest instance of the agency scaling back enforcement under President Donald Trump.
-
News BriefTexas sues Johnson & Johnson, Kenvue over alleged misleading marketing of Tylenol
Texas Attorney General Ken Paxton sued two pharmaceutical companies for ”deceptively marketing Tylenol to pregnant mothers” despite risks linked to autism. The filing came two days before HHS Secretary Robert F. Kennedy Jr. appeared to walk back the claims.
-
News BriefCFPB scraps bad-actor registry, citing cost-benefit issues
The Consumer Financial Protection Bureau shut down a registry of non-bank financial firms that broke consumer laws. The agency cites the costs being ”not justified by the speculative and unquantified benefits to consumers.”